Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

First Posted Date
2016-08-10
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1200
Registration Number
NCT02861573
Locations
🇨🇳

Merck Sharp & Dohme (I.A.) Corp., Taipei, Taiwan

🇺🇸

Call for Information (Investigational Site 0005), Los Angeles, California, United States

🇺🇸

Call for Information (Investigational Site 2041), Aurora, Colorado, United States

and more 25 locations

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

First Posted Date
2016-08-08
Last Posted Date
2019-06-14
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
55
Registration Number
NCT02858804
Locations
🇨🇳

Shuhua Yi, Tianjin, China

Optimal Treatment Strategy Based on for Pediatric AML

First Posted Date
2016-07-28
Last Posted Date
2016-07-28
Lead Sponsor
Samsung Medical Center
Target Recruit Count
350
Registration Number
NCT02848183
Locations
🇰🇷

Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of

🇰🇷

St. Mary Hospital, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

First Posted Date
2016-07-19
Last Posted Date
2016-07-19
Lead Sponsor
Pusan National University Hospital
Target Recruit Count
20
Registration Number
NCT02836639
Locations
🇰🇷

Pusan National University Hospital, Busan, Korea, Republic of

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

First Posted Date
2016-07-07
Last Posted Date
2017-11-14
Lead Sponsor
Ruijin Hospital
Target Recruit Count
40
Registration Number
NCT02825147
Locations
🇨🇳

Shanghai Ruijin Hospital, Shanghai, China

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

First Posted Date
2016-06-30
Last Posted Date
2020-03-12
Lead Sponsor
AbbVie
Target Recruit Count
28
Registration Number
NCT02819999
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

University Hospital of Cleveland, Cleveland, Ohio, United States

🇺🇸

Rocky Mountain Cancer Centers, Denver, Colorado, United States

and more 7 locations

Trial of BMS-986012 in Combination With Platinum and Etoposide

First Posted Date
2016-06-28
Last Posted Date
2024-05-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
12
Registration Number
NCT02815592
Locations
🇪🇸

Local Institution - 0002, Barcelona, Spain

🇪🇸

Local Institution - 0004, Madrid, Spain

🇪🇸

Local Institution - 0010, Malaga, Spain

and more 1 locations

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

First Posted Date
2016-06-13
Last Posted Date
2016-06-14
Lead Sponsor
GALIA AVRAHAMI
Target Recruit Count
2200
Registration Number
NCT02797717
Locations
🇮🇱

Schneider children's medical center, Petach-Tikva, Israel

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

First Posted Date
2016-06-13
Last Posted Date
2024-07-31
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
11
Registration Number
NCT02797470
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

First Posted Date
2016-06-09
Last Posted Date
2024-12-05
Lead Sponsor
Genentech, Inc.
Target Recruit Count
518
Registration Number
NCT02794571
Locations
🇰🇷

Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 25 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy